Viridian Therapeutics Inc Forecast, price target & analysts
Viridian Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Viridian Therapeutics Inc Classifications & Recommendation:
Viridian Therapeutics Inc Price Target
| Target Price | $39.69 |
| Price | $12.65 |
| Potential |
213.74%
register free of charge
|
| Number of Estimates | 16 |
|
16 Analysts have issued a price target Viridian Therapeutics Inc 2026 .
The average Viridian Therapeutics Inc target price is $39.69.
This is
213.74%
register free of charge
$61.00
382.21%
register free of charge
$22.00
73.91%
register free of charge
|
|
| A rating was issued by 17 analysts: 15 Analysts recommend Viridian Therapeutics Inc to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Viridian Therapeutics Inc stock has an average upside potential 2026 of
213.74%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.30 | 0.16 |
| 3.23% | 46.57% | |
| EBITDA Margin | -99,266.67% | -186,311.97% |
| 21.57% | 87.69% | |
| Net Margin | -82,879.77% | -210,829.88% |
| 40.26% | 154.38% |
14 Analysts have issued a sales forecast Viridian Therapeutics Inc 2025 . The average Viridian Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Viridian Therapeutics Inc EBITDA forecast 2025. The average Viridian Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Viridian Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Viridian Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.07 | -4.17 |
| 42.18% | 35.83% | |
| P/E | negative | |
| EV/Sales | 3,276.64 |
4 Analysts have issued a Viridian Therapeutics Inc forecast for earnings per share. The average Viridian Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Viridian Therapeutics Inc...
Current Viridian Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham |
Locked
➜
Locked
|
Locked | Jan 07 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Dec 19 2024 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Dec 17 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 17 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 16 2024 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Dec 05 2024 |
| Needham |
Locked
➜
Locked
|
Locked | Nov 25 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Needham:
Locked
➜
Locked
|
Jan 07 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Dec 19 2024 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Dec 17 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 17 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 16 2024 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Dec 05 2024 |
|
Locked
Needham:
Locked
➜
Locked
|
Nov 25 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
